There are several studies that have attempted to quantify the probability of malignization in large CMN but the results are variable, although we could establish this risk (understanding that we must consider the data with caution!!!) between 0 and 10%
[1] Liposomal technology directly addresses the absorption barrier
10.1016/j.amjcard.2015.12.031 21 DuJ.ZhangL.WangZ.YanoN.ZhaoY
GLP-1 is a multifaceted hormone, and the use of its analogs is associated with broad metabolic effects: they increase insulin secretion, decrease glucagon release, increase glucose uptake in muscles, decrease glucose production in the liver, improve lipid profile, slow gastric emptying, and increase satiety leading to weight loss ( GLP-1RA have been used to treat T2D for ~20 years, and they have transformed T2D management in pediatric and adult populations ( 4.1 HbA1c reduction 4.1.1 Uncontrolled studies In a small, uncontrolled study, weekly semaglutide in 10 patients with newly diagnosed T1D, mean HbA1c improved dramatically from 11.7 2.1% to 5.7 0.4% at 12 months ( 4.1.2 RCTs Several blinded, placebo-controlled RCTs have demonstrated a significant reduction in HbA1c when adding GLP-1RA to either multiple daily injections (MDI) or continuous subcutaneous infusion of insulin (CSII), ranging between 0.1-0.7% (61) ( Table 1 )

For the antibiotics screening method, due to the differential drug sensitivity of each cell line, it is usually necessary to conduct a pre-experiment to determine the working drug concentration before the formal experiment